1. Generics Bulletin
  2. >>Products

Prasco Has Authorized Generic NuvaRing

Competes With Amneal’s Recently-Approved First US Generic

 
• By Dave Wallace

Prasco has launched an authorized generic version of NuvaRing in the US, hot on the heels of Amneal’s launch of the first FDA-approved generic.

Start line
A second generic competitor has entered alongside Amneal • Source: Shutterstock

Prasco Laboratories has launched an authorized generic of Merck & Co’s top-selling, off-patent NuvaRing (etonogestrel/ethinylestradiol) vaginal ring in the US.

The launch pits it in direct competition with Amneal, which just won US Food and Drug Administration approval for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By Tom Gallen

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By Dean Rudge

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)